Non-small Cell Lung CancerNCT03427567
A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer
An observational study of Non-small Cell Lung Cancer, run by Tongji Hospital at 10 sites in China.
Trial summary
A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-small Cell Lung Cancer
- What is being tested?
- Sublobar dissection
- Type of treatment
- Surgery or procedure
- How many people
- 3,902 participants
- Where
- 10 sitesChina
- Study dates
- 1 Dec 2017to 30 Mar 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Chinese patients with pathological diagnosed non-small cell lung cancer who received sublobar dissection and lymphadenectomy
Who may be able to join
- Patients >= 18 years old;
- Patients who received sublobar dissection from 2014 to 2017 (segment dissection/wedge dissection/segment and wedge dissections);
- Patients who received selective or systematic lymphadenectomy;
- Pathologically diagnosed patients with non-small cell lung cancer;
- Pathological staging: I, II
Who cannot join
- Patients who received cancer treatments before surgeries (adjuvant therapies including chemotherapies, radiotherapies, target therapies);
- Patients who received late-phase or intolerant palliative lobectomy or compromise sublobar dissection;
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
China10 sites
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029
China PLA General Hospital
Beijing, Beijing Municipality, 100853
Huaxi Hospital Affiliated to Sichuan University
Chengdu, Sichuan, 610041
First Hospital Affiliated to Zhejiang University
Hangzhou, Zhejiang, 310003
Jiangsu cancer hospital
Nanjing, Jiangsu, 210009
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, 200030
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, 300051
Tongji Hospital Affiliated to Huazhong Technology Hospital
Wuhan, Hubei, 430030
Xi'an Tangdu Hospital
Xi'an, Shaanxi, 710000
Henan cancer hospital
Zhengzhou, Henan, 450003
About this study
Official title: A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer
A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer
Read the detailed description
This is a multi-centre real-world non-interventional observational study. The study data on patient demographic/tumor biological characteristics and clinical treatments were retrospectively collected to evaluate effectiveness of sublobar dissection in the Chinese patients with non-small cell lung cancer who received sublobar dissection.
- Conditions
- Non-small Cell Lung Cancer
- Being tested
- Sublobar dissection
- Keywords
- Chinese, real-world evidences, NSCLC, sublobar dissection
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sublobar dissectionProcedure or surgery
Also called Surgeries
Sublobar dissection plus lymphadenectomy
| Study group | Role | What they receive |
|---|---|---|
| Sublobar dissection | Chinese NSCLC patients who received sublobar dissection Receives: Procedure: Sublobar dissection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Overall survival
Measured: 2014 - 2017
Secondary outcomes (1)
Overall survivals in subgroups
Overall survivals categorised by tumor biological characteristics
Measured: 2014 - 2017
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2018
- Study start1 Dec 2017
- Primary completion1 Dec 2017
- Study completion30 Mar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Tongji HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 3,902 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tongji Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- LinkDoc Technology (Beijing) Co. Ltd.
- Responsible party
- Principal investigator, XiangNing Fu, Tongji Hospital
- Investigators
- Xiangning Fu, PhD, Principal investigator, Tongji Hospital Affiliated to Tongji Medical College Huazhong Technology University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03427567
- Sponsor's protocol ID
- TJ-LC-01
- Status last verified
- May 2018
- First submitted
- 2 Feb 2018
- Last updated
- 21 May 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT03427567
- Acronym / sponsor ID
- TJ-LC-01
- Conditions
- Non-small Cell Lung Cancer
- Keywords
- Chinese, real-world evidences, NSCLC, sublobar dissection
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,902 participants (actual)
- Lead sponsor
- Tongji HospitalUniversity, hospital or other
- Collaborators
- LinkDoc Technology (Beijing) Co. Ltd.
- Study start
- 1 Dec 2017 (actual)
- Primary completion
- 1 Dec 2017 (actual)
- Study completion
- 30 Mar 2018 (actual)
- First posted
- 9 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to evaluate effectiveness of sublobar dissection in patients with non-small cell lung cancer
Detailed description
This is a multi-centre real-world non-interventional observational study. The study data on patient demographic/tumor biological characteristics and clinical treatments were retrospectively collected to evaluate effectiveness of sublobar dissection in the Chinese patients with non-small cell lung cancer who received sublobar dissection.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Sublobar dissection | – | Procedure: Sublobar dissectionChinese NSCLC patients who received sublobar dissection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Chinese patients with pathological diagnosed non-small cell lung cancer who received sublobar dissection and lymphadenectomy
Key inclusion criteria (5 listed)
- Patients >= 18 years old;
- Patients who received sublobar dissection from 2014 to 2017 (segment dissection/wedge dissection/segment and wedge dissections);
- Patients who received selective or systematic lymphadenectomy;
- Pathologically diagnosed patients with non-small cell lung cancer;
- Pathological staging: I, II
Key exclusion criteria (2 listed)
- Patients who received cancer treatments before surgeries (adjuvant therapies including chemotherapies, radiotherapies, target therapies);
- Patients who received late-phase or intolerant palliative lobectomy or compromise sublobar dissection;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sublobar dissectionAlso: SurgeriesSublobar dissection plus lymphadenectomy | Procedure or surgery | Sublobar dissection |
Primary outcome
Overall survival
Time frame: 2014 - 2017
Overall survival
1 secondary outcome
Overall survivals in subgroups
Time frame: 2014 - 2017
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 May 2018.
- Individual participant dataSharing planned: No
Related trials for Non-small Cell Lung Cancer
RecruitingPhase 3
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
IO Resistant Squamous and Nonsquamous NSCLC
RecruitingPhase 3
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Non-small Cell Lung Cancer
Not yet recruitingPhase 1
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
RecruitingObservational study
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
RecruitingPhase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiangning Fu, PhD principal investigator
Tongji Hospital Affiliated to Tongji Medical College Huazhong Technology University
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-small Cell Lung Cancer, run by Tongji Hospital at 10 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 2014 - 2017). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2018.